Mozz, my concerns are what the FDA identified -including reference to non-clinical matters.
My main concern is that PAR are in effect looking for endorsement of marketing claims and FDA are in effect saying what's all this about.
Cheers for your on-going efforts.
Interview with an FDA Process Expert - Pre Questions, page-7
-
- There are more pages in this discussion • 8 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
25.5¢ |
Change
-0.010(3.77%) |
Mkt cap ! $89.19M | |||
| Open | High | Low | Value | Volume |
| 27.0¢ | 27.0¢ | 25.5¢ | $162.7K | 620.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 25008 | 25.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 26.0¢ | 34768 | 1 |
View Market Depth
| Last trade - 16.10pm 26/07/2024 (20 minute delay) ? |
| PAR (ASX) Chart |